Letter to House Members Opposing Language Added to the Appropriations Bill that Lowers the FDA’s Safety and Efficacy Standards for Drugs and Devices

April 15, 2016. The National Center for Health Research strongly opposes language added at the last minute to the House Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for fiscal year 2017. The language lowers the FDA’s safety and efficacy standards for approving drugs and medical devices and will put the public health at risk. These are the same provisions that members of the Patient, Consumer, and Public Health Coalition have previously opposed. We urge you to oppose including in the appropriations bill language that lowers FDA’s standards for drugs and devices.

Read More »

NCHR Supports Proposed FDA Regulation of Sunscreens

March 25, 2016. NCHR strongly supports the safety and effectiveness clinical and nonclinical testing requirements to obtain generally recognized as safe and effective (GRASE) status, as they are delineated in the draft guidance. The proposed testing requirements for new sunscreen chemicals will assure our country’s most vulnerable that the products will protect them from skin cancer and not cause unintended harm.

Read More »

NCHR Flu Vaccine Testimony

March 4, 2016. We applaud the FDA and CDC for changing the recommendations for children, to reflect the poor efficacy of the live attenuated influenza vaccine (nasal spray). There is another problem however, that I want to talk about today. The CDC has strongly encouraged patients to use antiviral medications if they get the flu. However, the evidence shows how little benefit Tamiflu offers, as well as significant risks for children.

Read More »